Calgon Carbon to relocate headquarters to Moon
Calgon Carbon Corp. will relocate its world headquarters from Robinson to the nearly completed Westpointe Corporate Center Four building in Moon in early 2015.
The company announced on Monday it will locate about 200 employees in the building, considered one of the most environmentally green buildings in the region. The employees include the executive staff, sales, service and research and development.
“We are an evolving high-technology company committed to researching and developing the best solutions for helping make the world's water and air safer and cleaner,” said Randall Dearth, chairman, president and CEO.
The company's products include activated carbon and specialty products, ion exchange technology systems, activated carbon absorption equipment and ultraviolet technologies, according to Calgon Carbon's website.
Its clients include municipalities, government agencies, and food, chemical, and drug manufacturers needing purification solutions.
Dearth said that combining the research laboratory with the corporate staff will help build “a collaborative organization dedicated to identifying and supporting the efforts of our customers as they work to improve their communities.”
The five-story building constructed by DiCicco Development Inc. is located on 10 acres at 3000 GSK Drive, close to FedEx Ground and a Homewood Suites hotel, near Route 60 and Montour Run Road.
Sam Spatter is a Trib Total Media staff writer. Reach him at 412-320-7843 or email@example.com.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- PPG puts brand 1st in strategy to reach commercial paint market
- Travelers find Internet direct route to Priory’s spirited past in Pittsburgh’s North Side
- EPA ordered to ease limits on cross-border air pollution that involves Pennsylvania
- Consol Energy, Range Resources report 2Q losses, plan deeper cuts
- Muni bond funds stressed
- U.S. Steel posts quarterly loss, declares dividend
- Pa. improves performance among competitive electric markets
- Stocks end 5-day slide on strong Ford, UPS earnings
- U.S. Steel joins major producers in new dumping complaint
- Invasive beetle costs Pittsburgh-area power companies plenty
- Bayer sets sights beyond aspirin